Fellow RAC shareholder @johndprent and his sparring partner @AlCp seem to have put in a lot of work over there recently. Though there seems to be some minor disagreement between them on the finer points. What I've gathered from a cursory read so far:
* Well funded * Low SOI * Top-notch management * Low overheads * Significant insider buying * Multiple shots on goal * Never released a bad announcement * Developing a cure for cancer, aiming for 90% of the solid tumour market * Potential catalysts include one or more "excellent" clinical trial updates anticipated in the near future * Shares are currently being offered "cheap", so as to provide long term holders more upside (that's right isn't it @AlCp?)
Apologies for any misrepresentations, errors or omissions in the above. DYOR.
RAC Price at posting:
$1.39 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)